Necrotising Enterocolitis Market Growth Dynamics Share Value, Size, Business Opportunities and Industry Forecast to 2030
Necrotizing Enterocolitis Market Overview
The necrotizing
enterocolitis market is one of the rapidly improving market structures
which is projected to achieve better future results due to the rising number of
cases of morbidity and mortality among infants and premature babies which leads
to continuous investments being made towards the establishment and growth of
the necrotizing enterocolitis market size and share.
Necrotizing Enterocolitis is a form of severe inflammation caused in the
inner lining of the intestinal wall. Due to such inflammation, a hole is formed
on the intestinal wall due to which there is a leakage of usual bacteria which
are present in the intestine for better digestion to the abdomen and other body
parts and hence causes infection to other body organs. The infection spreads in
the entire body and creates a medical emergency and if not treated properly can
also be life-threatening and in adverse situations may also cause the death of
the baby.
Necrotizing Enterocolitis is said to affect newborn babies particularly
within one week of their birth. The most common symptoms of a baby suffering
from necrotizing enterocolitis are poor tolerance to feelings, blood in stool,
redness in the stomach region, and in extreme cases it can also lead to apnea
and sleep disorders. Rapid investments in terms of technology and logistics
have provided a major boost to the necrotizing enterocolitis market
Request Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/5999
Segmentation
The global Necrotising Enterocolitis (NEC) market is segmented on the basis
of stage, diagnosis, treatment, and end-user.
Based on stage, the market is classified as Stage I, Stage II, and Stage
III. The Stage II is further segmented into Stage IIa and Stage IIb. The Stage
III is further segmented into Stage IIIa and Stage IIIb.
Based on diagnosis, the market is classified as imaging, laboratory studies,
and differential diagnosis. The imaging segment is further classified as
abdominal x-ray, Magnetic Resonance Imaging (MRI), ultrasound, laparoscopy,
angiography, and others. The laboratory studies segment is further classified
as haemochromocytometric exam, blood culture, serum electrolytes, arterial
blood gas analysis, blood pressure monitor, and others. The differential
diagnosis segment is further classified as ileus secondary to neonatal sepsis,
spontaneous intestinal perforation, ileal atresia, intestinal malrotation,
volvulus, neonatal appendicitis, neonatal pseudomembranous colitis, and others.
Based on treatment, the market is classified as Total Parenteral Nutrition
(TPN), gastrointestinal decompression, antimicrobial therapy, antifungal
treatment, paracentesis, and others.
Based on end-user, the market is classified as hospitals and clinics,
ambulatory surgical center, diagnostic centers, and others.
Regional Analysis
The global Necrotising Enterocolitis (NEC) market consists of regions,
namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas dominated the global Necrotising Enterocolitis (NEC) market
owing to the use of numerous therapies for the treatment of Necrotising
Enterocolitis (NEC) along with the demand for early diagnosis. For instance, in
2013, Necrotising Enterocolitis (NEC) was the cause of 355 deaths per 100,000
live births in the United States. The death toll was virtually three times
higher in the black population than for the white population.
The European region is the second largest market for global Necrotising
Enterocolitis (NEC) due to the surging demand for antifungal drugs. Moreover,
factors favoring the growth of Necrotising Enterocolitis (NEC) in the Asia
Pacific region are the implementation of various healthcare reforms such as
Patient Protection and Affordable Care Act (PPACA), increasing investments in the
Asia Pacific region offering huge market potential, and rapidly increasing
aging population.
The Middle East and Africa is projected to show steady growth in this market
due to a subsequent rise in the number of neonatal diseases along with the
growing healthcare infrastructure in remote areas.
Key Players
Some of the key players in the global necrotising enterocolitis (NEC) market
are Abbott Laboratories Inc. (U.S.), Astellas Pharma Inc. (Japan), Bayer
HealthCare AG (Germany), Becton, Dickinson and Company (BD) (U.S.),
Bristol-Myers Squibb Company (U.S.), Daiichi Sankyo Company , Ltd. (Japan), Eli
Lilly and Co. (U.S.), Enzon Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche
Ltd (Switzerland), GI Supply (U.S.), GlaxoSmithKline Plc (UK), Kyorin Pharmaceutical
Co., Ltd. (U.S.), Medtronic Plc (U.S.), Merck & Co. Inc. (U.S.),
MiddleBrook Pharmaceuticals (Japan), Novartis AG (Switzerland), Pfizer Inc.
(U.S.), Sanofi-Aventis (France), Sequana Medical AG (Switzerland), Takeda
Pharmaceutical Company, Ltd. (Japan), and others.
Browse Detailed TOC with COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/necrotising-enterocolitis-market-5999
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private
Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 646 845 9312
Email: sales@marketresearchfuture.com
Comments
Post a Comment